Medication adherence remains one of the healthcare industry’s greatest challenges, impacting clinical trials, commercial therapies, and patient outcomes across pharmaceutical and biotechnology companies. AiCure Corporation has spent years addressing this challenge with its pioneering medication adherence solutions, which leverage AI to remotely monitor medication adherence through a patient’s smartphone. AiCure’s new WeightVerify™ platform combines facial verification and OCR technology to deliver trusted remote weight monitoring for obesity, diabetes, cardiovascular disease, and other chronic conditions—helping both providers and patients improve engagement and outcomes.
Founded over 16 years ago, AiCure has raised over $70 million in venture capital with an initial NIH grant, and was recently acquired by Vive VC, a Silicon Valley venture capital firm. AICure has partnered with healthcare providers and more than 70 pharmaceutical and biotechnology companies, supporting clinical trials across more than 2,200 sites in over 46 languages and countries. Backed by a portfolio of more than 85 patents, AiCure works with 7 out of 10 of the world’s leading pharmaceutical companies.
We sat down with AiCure’s CEO, Sabina Chadha, to discuss how artificial intelligence is transforming the life sciences market, clinical research, chronic disease management, the future of digital health, and what’s next for the company.
Why did you join AiCure?
I joined AiCure because I saw an opportunity to grow a company already tackling one of healthcare’s most persistent and expensive challenges: helping patients stay on therapy while giving life sciences companies and providers data they can actually trust. AiCure had already established world-class AI technology, a strong patent portfolio, and deep relationships across life sciences. My goal has been to build on that foundation, expand our platform, and position AiCure as the trusted clinical infrastructure for patient-generated health data.
What problem is AiCure solving that others aren’t?
AiCure is fundamentally different because we don’t simply collect patient data—we verify it. That distinction matters because in regulated healthcare environments, trusted data is more valuable than untrusted data. Our computer vision and AI platform helps confirm medication adherence and now remotely verifies weight readings using patients’ existing smartphones and scales. In fact, within a structured behaviorial weight-loss program, daily self weighing was associated with approximately 13 pounds greater weight loss over six months compared with weighing less frequently, according to a study conducted by Dr. Dori M. Steinberg affiliated with the Duke Obesity Prevention Program and the University of North Carolina at Chapel Hill.
Furthermore, our solutions are designed for regulated healthcare environments, integrate into clinical workflows, and have been validated through years of deployment with leading pharmaceutical companies and providers.
Why does verification matter so much in healthcare?
Because healthcare decisions, clinical trials, and chronic disease programs depend on confidence. If the data is incomplete or uncertain, it limits what sponsors, providers, and researchers can do with it. AiCure helps close that gap by turning patient-generated inputs into something teams can rely on, whether the use case is medication adherence, decentralized trials, or chronic care management.
What kind of organizations are using AiCure?
Our customers include seven of the ten leading pharmaceutical companies in the world, biotechnology companies, contract research organizations (CROs), and healthcare providers. They rely on AiCure to improve patient engagement and medication adherence, increase confidence in clinical data, support decentralized trials, accelerate drug development, and improve patient outcomes in chronic disease management programs. That broad adoption shows the need is real across both clinical and commercial settings.
What makes this an attractive category for investors?
AI in healthcare gets attention when it feels futuristic, but the real opportunity is in solving operational problems that already exist. Investors recognize that AI is transforming healthcare by improving clinical decision support and enabling better patient outcomes, but long-term value will come from organizations solving real operational problems. As care moves farther from the clinic and more research becomes decentralized, trusted patient-generated data becomes a core asset. AICure sits at the intersection of AI, digital health, and life sciences with proven commercial adoption and regulatory experience, enabling improved patient outcomes across the healthcare continuum.
What is AiCure’s core business today?
Our core business is AiCure’s H.Code platform, which leverages artificial intelligence and computer vision to remotely track patient behavior and medication adherence during clinical trials via a patient’s smartphone. In contrast to traditional methods, where clinical staff must manually call patients, a process that is time-consuming, inefficient, and yields limited data, H.Code delivers real-time objective adherence information and automated monitoring. This enables study teams to conduct clinical trials more quickly, reliably, and cost-effectively.
We provide pharmaceutical and biotechnology companies, contract research organizations, study teams, and healthcare organizations globally with advanced tools and insights that enhance patient engagement, medication adherence, and overall clinical trial performance across various therapeutic areas.
AiCure enhances the effectiveness and efficiency of clinical trials by minimizing participant dropouts, improving medication adherence, reducing costs, and speeding up the drug development process, all while increasing accessibility and promoting inclusivity in clinical research.
What’s next for AiCure?
Our next chapter is expanding beyond medication adherence with WeightVerify™, enabling trusted remote weight verification for obesity, diabetes, cardiovascular disease, and GLP-1 care management while positioning AiCure as a broader patient-generated data clinical infrastructure platform.
We’ll continue investing in life sciences while growing partnerships across providers and digital health companies, and offer white-label enterprise solutions for CROs, pharma and biotech organizations, and providers across our product lines to make verified medication adherence and remote weight monitoring data easier to collect at scale in order to improve patient outcomes.
Looking ahead five to ten years, what excites you most about AI in healthcare?
I believe we’re entering an era where trusted patient-generated data will become a foundational component of healthcare. Care will increasingly happen wherever patients are.
Clinical research will become more accessible. Remote monitoring will continue expanding. Artificial intelligence will help clinicians make better-informed decisions rather than replace them.
The companies that create lasting value will build the infrastructure that allows healthcare organizations to confidently rely on information collected outside traditional clinical settings.
That’s the future we’re building toward. Medication adherence was the beginning of our journey. Helping healthcare trust patient-generated data wherever care happens is the opportunity that lies ahead.
What advice would you offer to entrepreneurs building AI companies in the life science and healthcare industry?
Start with the problem—not the technology.
Life sciences and healthcare organizations don’t need AI searching for an application. They need solutions addressing real operational challenges faced by the life sciences industry, clinicians, researchers, patients, and healthcare organizations.
Build alongside customers. Validate rigorously. Measure outcomes.
More Articles:
Copyright © by Richard D. Harroch. All Rights Reserved.